Impaired Hepatic Function Since impaired hepatic function has been associated with some cases of lactic acidosis, Janumet should generally be avoided in patients with clinical or laboratory evidence of hepatic disease
Current practice converges around three tiers: The split-dose protocol (250 mcg morning, 250 mcg 3+ hours post-meal in the evening) creates two daily windows of lipolytic stimulation
Long-Term Safety, Cancer Questions, and Heart Monitoring Long-term retatrutide safety is still being studied
It helps your body enter deep, restorative sleep so you wake up refreshed
Read more on the ACHIEVE-3 results here: To view or add a comment, sign in Novo Nordisks next-generation obesity drug CagriSema failed to outperform Eli Lillys Zepbound in a recent head-to-head Phase 3 trial, missing its primary goal and underscoring the intense competition and high stakes in the obesity drug market
How long does it take to reach the maximum GLP-1 dose